We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies. Cookie Policy.

Features Partner Sites Information LinkXpress
Sign In
Advertise with Us
PURITAN MEDICAL

Download Mobile App





New Ultra-High-Throughput PCR Testing System for SARS-CoV-2 Detection Can Test up to 150,000 Patient Samples per Day

By LabMedica International staff writers
Posted on 16 Sep 2021
Print article
Illustration
Illustration
A new ultra-high-throughput PCR testing system for SARS-CoV-2 detection can test up to 150,000 patient samples per day.

The proven molecular genomics testing platform with unmatched capacity that has been developed by LGC, Biosearch Technologies (Hertfordshire, UK) is expected to redefine large-scale COVID-19 testing. For labs ready to scale to support mass testing, the company is offering the ultra-high-throughput (uHTP) end-point PCR testing system for SARS-CoV-2 detection.

The Biosearch Technologies workflow combines the Nexar industrial scale, automated end-point PCR testing platform with our robust, high-quality testing reagent components. UgenTec’s FastFinder software seamlessly integrates with the company’s instrumentation to provide full traceability of the sample down to individual wells on the Array Tape consumable, which allows the user to easily pull up a sample’s status. Biosearch Technologies’ SARS-CoV-2 testing workflow can expand testing capacity to as many as 150,000 samples per day with minimal need for additional staff, instrumentation, or lab space.

Biosearch Technologies' SARS-CoV-2 testing system is good for screening symptomatic and asymptomatic individuals. It is compatible with anterior nares specimens self-collected in a non-medical setting or by a healthcare professional within a healthcare setting. The system features an easy dry swab collection device that is safe for handling, better for shipping, and automation-friendly. Biosearch Technologies’ SARS-CoV-2 testing workflow features an extraction-free process without compromising sensitivity of a 250 cp/swab limit of detection (LoD).

Related Links:
LGC, Biosearch Technologies

Platinum Member
COVID-19 Rapid Test
OSOM COVID-19 Antigen Rapid Test
HLX
POCT Fluorescent Immunoassay Analyzer
FIA Go
Gold Member
SARS‑CoV‑2/Flu A/Flu B/RSV Sample-To-Answer Test
SARS‑CoV‑2/Flu A/Flu B/RSV Cartridge (CE-IVD)

Print article

Channels

Clinical Chemistry

view channel
Image: Reaching speeds up to 6,000 RPM, this centrifuge forms the basis for a new type of inexpensive, POC biomedical test (Photo courtesy of Duke University)

POC Biomedical Test Spins Water Droplet Using Sound Waves for Cancer Detection

Exosomes, tiny cellular bioparticles carrying a specific set of proteins, lipids, and genetic materials, play a crucial role in cell communication and hold promise for non-invasive diagnostics.... Read more

Molecular Diagnostics

view channel
Image: The study showed the blood-based cancer screening test detects 83% of people with colorectal cancer with specificity of 90% (Photo courtesy of Guardant Health)

Blood Test Shows 83% Accuracy for Detecting Colorectal Cancer

Colorectal cancer is the second biggest cause of cancer deaths among adults in the U.S., with forecasts suggesting 53,010 people might die from it in 2024. While fewer older adults are dying from this... Read more

Hematology

view channel
Image: The Gazelle Hb Variant Test (Photo courtesy of Hemex Health)

First Affordable and Rapid Test for Beta Thalassemia Demonstrates 99% Diagnostic Accuracy

Hemoglobin disorders rank as some of the most prevalent monogenic diseases globally. Among various hemoglobin disorders, beta thalassemia, a hereditary blood disorder, affects about 1.5% of the world's... Read more

Microbiology

view channel
Image: The new platform is designed to perform blood-based diagnoses of nontuberculosis mycobacteria (Photo courtesy of 123RF)

New Blood Test Cuts Diagnosis Time for Nontuberculous Mycobacteria Infections from Months to Hours

Breathing in nontuberculous mycobacteria (NTM) is a common experience for many people. These bacteria are present in water systems, soil, and dust all over the world and usually don't cause any problems.... Read more

Industry

view channel
Image: These new assays are being developed for use on the recently introduced DxI 9000 Immunoassay Analyzer (Photo courtesy of Beckman Coulter)

Beckman Coulter and Fujirebio Expand Partnership on Neurodegenerative Disease Diagnostics

Beckman Coulter Diagnostics (Brea, CA, USA) and Fujirebio Diagnostics (Tokyo, Japan) have expanded their partnership focused on the development, manufacturing and clinical adoption of neurodegenerative... Read more
Copyright © 2000-2024 Globetech Media. All rights reserved.